Try
Royalty Pharma plc Ordinary Shares
RPRXUnited States
26 filed reports · 293 financial concepts · 2 earnings calls · 3 media appearances
Filed reports
26 reports · Jun 2020 to Jun 2026Each report counts once it has at least one extracted financial fact. Also extracted from these reports: 2 guidance figures.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 19 | 3,151 | Jun 2020 to Jun 2026 |
| Annual · 10-KSEC EDGAR | 6 | 2,349 | Dec 2020 to Dec 2025 |
| Current · 8-KSEC EDGAR | 1 | 2 | Sep 2025 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q2 | 10-Q | Jun 30, 2026 | Aug 5, 2026 | 319 | Open |
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 6, 2026 | 226 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 11, 2026 | 718 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 5, 2025 | 250 | Open |
| FY2025 Q3 | 8-K | Sep 30, 2025 | Nov 5, 2025 | 2 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 145 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 8, 2025 | 135 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 12, 2025 | 362 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 141 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 8, 2024 | 129 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 126 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Feb 15, 2024 | 343 | Open |
Financial data
293 concepts · 5,502 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial289 concepts · 5,387 facts · Dec 2018 to Jun 2026
- Cystic fibrosis franchise62 · Jun 2020 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents38 · Dec 2018 to Jun 2026
- Stockholders equity including portion attributable to noncontrolling interest38 · Dec 2018 to Jun 2026
- Costs and expenses37 · Dec 2018 to Jun 2026
- Equity securities fv ni unrealized gain loss37 · Dec 2018 to Jun 2026
- General and administrative expense (US GAAP)37 · Dec 2018 to Jun 2026
- Income loss from equity method investments37 · Dec 2018 to Jun 2026
- Income tax expense benefit37 · Dec 2018 to Jun 2026
- Minority interest decrease from distributions to noncontrolling interest holders37 · Dec 2018 to Jun 2026
- Net income loss37 · Dec 2018 to Jun 2026
- Net income loss attributable to noncontrolling interest37 · Dec 2018 to Jun 2026
- Nonoperating income expense37 · Dec 2018 to Jun 2026
- Operating income loss37 · Dec 2018 to Jun 2026
- Other nonoperating income expense37 · Dec 2018 to Jun 2026
- Profit loss37 · Dec 2018 to Jun 2026
- Research and development expense37 · Dec 2018 to Jun 2026
- Revenue37 · Dec 2018 to Jun 2026
- Amortization of financing costs and discounts36 · Dec 2018 to Jun 2026
- Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect36 · Dec 2018 to Jun 2026
- Cash collected on financial royalty assets36 · Dec 2018 to Jun 2026
- Cash collections from financial royalty assets36 · Dec 2018 to Jun 2026
- Cash collections from intangible royalty assets36 · Dec 2018 to Jun 2026
- Contributions from non-controlling interests- other36 · Dec 2018 to Jun 2026
- Contributions from non-controlling interests- R&D36 · Dec 2018 to Jun 2026
Product3 concepts · 113 facts · Dec 2018 to Jun 2026
- Revenue99 · Dec 2018 to Jun 2026
- Milestone payable - Erleada11 · Dec 2022 to Dec 2025
- Research and development expense3 · Jun 2025 to Mar 2026
Guidance1 concepts · 2 facts · Nov 2025
- Revenue Guidance2 · Nov 2025
Segments
113 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service7 members · 113 facts
- Financial Royalty Assets37 · Dec 2018 to Jun 2026
- Royalty Income Other37 · Dec 2018 to Jun 2026
- Intangible Royalty Assets25 · Dec 2018 to Dec 2023
- Erleada7 · Dec 2022 to Dec 2025
- Trelegy4 · Dec 2022 to Dec 2025
- Daraxonrasib2 · Jun 2025 to Dec 2025
- Phase2b TEV4081 · Mar 2026
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
- Earnings-release commentary132 claims from 9 reports · Sep 2024 to Jun 2026
- Management discussion (MD&A) commentary183 claims from 6 reports · Mar 2025 to Jun 2026
- Risk-factor changes23 claims from 1 reports · Dec 2025
- Risk factors124 risks from 2 annual reports · 2024 to 2025
Earnings calls
2 calls · May 2026 to Aug 2026Transcripts with management claims and analyst questions, one per fiscal period.
- FY2026 Q2Aug 5, 2026
- FY2026 Q1May 6, 2026
Executive media
3 appearancesPodcasts, interviews and conference appearances by the company's executives, with their claims.
- Other appearances2 · Jun 2020 to Oct 2022
- TV interviews1 · Jun 2020
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Oct 16, 2026) and refreshed every few hours.